Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treated with isatuximab.
Progression-Free Survival in MM when Treating with Isatuximab
